Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer
- Registration Number
- NCT05849129
- Lead Sponsor
- The Canadian College of Naturopathic Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria:<br><br> 1. Adults (=18 years of age) seen at TOHCC with stage IIIB or IV primary non-small cell<br> lung cancer<br><br> 2. Eligible and scheduled for first line platinum-doublet chemotherapy with or without<br> concurrent immunotherapy<br><br>Exclusion Criteria:<br><br> 1. ECOG status greater than 2<br><br> 2. Previously received IVC within 6 months prior to randomization<br><br> 3. Biochemical deficiency in G6PD<br><br> 4. Estimated Glomerular Filtration Rate (eGFR) less than 45 mL/min<br><br> 5. Currently taking insulin or warfarin<br><br> 6. History of severe renal dysfunction or hemochromatosis<br><br> 7. Previously undergone cytotoxic chemotherapy or immunotherapy within 12 months prior<br> to randomization<br><br> 8. If pregnant or planning to become pregnant: not a carrier of the gene for G6PD<br> deficiency<br><br> 9. Currently taking an investigational product or participation in an investigational<br> study within the past 30 days<br><br> 10. Any reason which, under the discretion of the Principal Investigator or delegate,<br> would preclude the patient from participating
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in Quality of Life
- Secondary Outcome Measures
Name Time Method Chemotherapy-Related Toxicities;Frequency of Discontinuation of Chemotherapy;Change in General Symptom Burden;Change in C-Reactive Protein Levels;Tumour Progression;Survival;Safety;Cytotoxicity